BSN Tracker

semaglutide

Brand: Ozempic (SC weekly), Rybelsus (oral), Wegovy (SC weight management)

⚠ BBW Prototype: liraglutide
Drug Class: antidiabetic / weight management
Drug Family: antidiabetic
Subclass: GLP-1 receptor agonist
Organ Systems: endocrine

Mechanism of Action

Activates GLP-1 receptors on pancreatic beta cells (stimulating glucose-dependent insulin secretion), alpha cells (suppressing glucagon), and hypothalamic centers (reducing appetite); also slows gastric emptying; long half-life of weekly SC formulation achieved through albumin binding via C-18 fatty acid modification.

glucagon-like peptide-1 receptor (GLP-1R)

Indications

  • type 2 diabetes mellitus (glycemic control)
  • cardiovascular risk reduction in T2DM with established CVD (Ozempic)
  • chronic weight management (Wegovy)
  • non-alcoholic steatohepatitis (emerging: NASH/MASH)

Contraindications

  • personal or family history of medullary thyroid carcinoma or MEN 2 syndrome
  • history of serious hypersensitivity to semaglutide

Adverse Effects

Common

  • nausea (very common — especially at initiation and dose escalation)
  • vomiting
  • diarrhea
  • constipation
  • injection site reactions

Serious

  • pancreatitis (rare; hold if suspected)
  • gastroparesis and delayed gastric emptying (major anesthesia concern)
  • acute gallbladder disease (cholelithiasis, cholecystitis)
  • thyroid C-cell tumors (rodent data; human significance unclear)
  • diabetic retinopathy progression (rapid glycemic improvement)

Pharmacokinetics (ADME)

Absorption SC Ozempic: ~89% bioavailability; oral Rybelsus: ~1% bioavailability (significant first-pass; take 30 min before first food with no more than 4 oz water)
Distribution ~99% albumin-bound; Vd ~12.5 L
Metabolism Proteolytic cleavage and fatty acid beta-oxidation
Excretion Renal (~3%) and fecal
Half-life ~1 week (SC) — enables once-weekly dosing
Onset Weeks for full effect; glucose-lowering within days
Peak 1–3 days (SC)
Duration 1 week (SC)
Protein Binding ~99%
Vd ~12.5 L

Drug Interactions

Drug / Agent Mechanism Severity
oral medications with narrow therapeutic index (warfarin, phenytoin) delayed gastric emptying reduces absorption rate of oral drugs — monitor levels closely moderate
insulin / sulfonylureas additive hypoglycemia risk; reduce insulin/SU dose by 20–40% when adding semaglutide moderate

Nursing Considerations

  1. Titrate dose slowly (starting at 0.25 mg weekly for Ozempic) to minimize GI side effects — nausea is dose-dependent and usually improves after 4–8 weeks at each dose level
  2. Inform anesthesiology team before any elective surgery — GLP-1 receptor agonists cause gastroparesis and significantly increase aspiration risk; many institutions recommend holding for 1 week before surgery with standard fasting intervals
  3. Educate patients about pancreatitis warning signs (persistent severe abdominal pain radiating to the back, nausea, vomiting) — hold and seek emergency care
  4. For Wegovy (weight management): indications include BMI ≥30 or ≥27 with weight-related comorbidity; set realistic expectations — average ~15% weight loss with Wegovy vs. ~2.5% with placebo

Clinical Pearls

  • Semaglutide is the first oral GLP-1 receptor agonist (Rybelsus) — this required overcoming the GLP-1 peptide's susceptibility to GI degradation via co-formulation with the SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) absorption enhancer
  • The SELECT trial (2023) demonstrated that semaglutide (Wegovy) reduces major adverse cardiovascular events in overweight/obese non-diabetic patients with established CVD — the first evidence of GLP-1 RA CV benefit independent of diabetes

Safety Profile

Pregnancy use-with-caution
Lactation avoid
Renal Adjustment Not required
Hepatic Adjustment Not required
TDM Not required
Guideline Update pending

Concordance Terms

Cross-referenced clinical concepts — click any term to see all content where it appears.

Antidiabetic / Weight Management Cardiovascular Risk Reduction In T2DM With Established CVD (Ozempic) Chronic Weight Management (Wegovy) Non-alcoholic Steatohepatitis (emerging: NASH/MASH) Type 2 Diabetes Mellitus (glycemic Control)
← Back to Medications